Redx Pharma has been granted a patent for compounds that can inhibit the Wnt signaling pathway, specifically targeting Porcupine (Porcn). These compounds can be used to treat various conditions mediated by the Wnt signaling pathway, including cancer, sarcoma, melanoma, skin cancer, hematological tumors, lymphoma, carcinoma, and leukemia. The patent also covers the processes to prepare these compounds and their use in enhancing the effectiveness of anti-cancer treatments. GlobalData’s report on Redx Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Redx Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Redx Pharma's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11643408B2) discloses a method for treating various conditions mediated by the Wnt signaling pathway, including cancer, sarcoma, melanoma, skin cancer, hematological tumors, lymphoma, carcinoma, and leukemia. The method involves administering a therapeutic amount of a pharmaceutical formulation containing a compound of formula (III).
The patent claims specify the conditions that can be treated using this method, which include esophageal squamous cell carcinoma, gastric cancer, glioblastomas, astrocytomas, retinoblastoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, rhabdomyosarcoma, Wilms tumor, basal cell carcinoma, non-small cell lung cancer, brain tumor, hormone refractory prostate cancer, prostate cancer, metastatic breast cancer, breast cancer, metastatic pancreatic cancer, pancreatic cancer, colorectal cancer, cervical cancer, head and neck squamous cell carcinoma, and cancer of the head and neck.
The compound of formula (III) is further described in the patent claims as being represented by formula (Va) or formula (Vc). The claims also provide additional details about the chemical structure of the compound, including the presence of specific functional groups and substitutions.
The patent claims also mention the administration routes for the pharmaceutical formulation. Claim 17 states that the formulation can be administered orally, while claim 18 specifies that it can be administered parenterally.
Overall, this granted patent presents a method for treating various conditions mediated by the Wnt signaling pathway using a specific compound. The claims provide specific details about the conditions that can be treated, the chemical structure of the compound, and the possible administration routes for the pharmaceutical formulation.
To know more about GlobalData’s detailed insights on Redx Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
